Mesa Laboratories is a regulation-embedded quality-control franchise that just changed captains after nine years, and the first print under Siddhartha Kadia already frames the debate. The company sells sterilization indicators, protein-analysis systems, calibration instruments, and a genomics platform that laboratories and drug manufacturers qualify into validated processes. What changed is not the product set. It is the operating contract. Gary Owens, who built The Mesa Way and the acquisition machine, handed the chair to Kadia in mid-April after a board-run external search. Kadia's first public read after roughly one hundred days is that the franchises are durable and the problems are fixable. The market is paying up for repair of a business that just printed roughly one percent organic growth.
The tension sits in the mix, not the headline. Sterilization and Disinfection Control, the largest and most compliance-locked division, slipped on fulfillment and delivery timing even after a fourth-quarter backlog flush. Calibration Solutions and Biopharmaceutical Development carried the period with mid-single-digit organic gains and fatter gross margins. Clinical Genomics, leftover from the Agena purchase, finally stopped shrinking in a material way as China declines slowed. Adjusted operating income excluding special items reached 26% of sales. GAAP net income still fell because a prior-year currency gain on an intercompany loan did not repeat. Cash generation funded another debt paydown that pushed net leverage below the stated two-times target.
The next several months decide whether Kadia is repairing a high-quality platform or narrating around a low-growth compounder. He has deferred full-year guidance until the November first-half print. The variables that resolve the case are sterilization shipment recovery, company-level core organic growth staying positive, and whether the mid-twenties adjusted margin holds once spending to fix fulfillment rises. Shares last changed hands near $127, for equity value of about $708 million. That price already assumes the operational repair actually works.